MIELOMANEWS

Bart Barlogie

Professional Experience

1970-1971 Internship, Internal Medicine, University of Munich, Munich, Germany

Residency, Internal Medicine, Rheumatology, 1971-1974 Nephrology, Cardiology, Hematology, Infectious Diseases, Gastroen-

terology, University of Muenster Medical School 1976-1977 Project Investigator, Dept. of Developmental Therapeutics, MD Anderson Hospital & Tumor Institute, Houston, TX

1977-1979 Assistant Professor, Medicine, Dept. of Developmental Therapeutics, MD Anderson

Assistant Professor, Dept. of Internal Medicine, 1978-1982 University of Texas Medical School, Houston, TX; Acting Chief of **Oncology Service**

1979-1983 Associate Professor, Medicine, Dept. of Developmental Therapeutics, MD Anderson

1979-1983 Associate Professor, Medicine, Dept. of Internal Medicine, University of Texas Medical School

Professor, Medicine, Graduate School of Biomedi-1978-1989 cal Sciences, University of Texas

1983-1989 Professor, Medicine, Dept. of Hematology, MD

Anderson

Ad Interim Chairman, Dept. of Hematology, MD 1985-1987

Anderson

Chief, Experimental Hematology, Dept. of 1985-1989

Hematology, Div. of Medicine, MD Anderson

Adjunct Professor, Medicine, Dept. of Hematolo-1989-present

gy, Div. of Medicine, MD Anderson

1989-1997 Professor, Medicine and Pathology, Director, Div. of Hematology/Oncology, University of Arkansas for Medical Sciences (UAMS); Director of Research, Arkansas Cancer Research

Center (ACRC), UAMS 1997-1998 Professor, Medicine and Pathology, Director, Myeloma & Transplantation Research Center, UAMS; Director of

1998-2001 Professor, Medicine and Pathology, Director,

ACRC, UAMS

Research, ACRC


Professor, Medicine and Pathology, Director, 2001-present

Myeloma Institute for Research and Therapy, UAMS

Simposio Internacional

"Mieloma Múltiple, una cura es posible"

Jueves 24 de mayo de 2012 a las 19.30 horas. Hotel Sheraton—Santiago.



Honors

The Best Doctors in America, 1994, 1998 Distinguished Faculty Scholar Award UAMS, 1995 Distinguished Faculty, Arkansas Caduceus Club, 1997 Distinguished Alumnus Award, MD Anderson Cancer Center, 1998 Jan Waldenström Award for Myeloma Research, 1999 Celgene Career Achievement Award in Hematology Research, 2002 Francesca M. Thompson Outstanding Service Award (IMF), 2003 Robert A. Kyle Lifetime Achievement Award (IMF), 2004 Castle Connolly Medical Ltd., National Physician Award of the Year -

Tommy May Chair in Oncology, 2006

Research Support, Ongoing

(Qiang, PI) 2/1/11-3/31/13 Multiple Myeloma Research Foundation Grant

Identification of Molecular Targets in Myeloma Microenvironment

The aim of this project is to identify molecular targets in cadherin-modulated signaling pathways that contribute to myeloma pathogenesis in

bone marrow microenvironments. Role: Co-Investigator

5P01CA095819-17 (Barlogie, PI) 9/1/09-8/31/14


NCI

Growth Control in Multiple Myeloma

The overall objective of this P01 is to understand mm growth in the context of its interaction with the bone marrow microenvironment (ME) in order to translate and exploit this knowledge into smarter MM growth control in patients. A concerted effort by a highly integrated and synergistic team of basic and clinical scientists is aimed at further overcoming the tremendous obstacles posed by MM's extensive genetic heterogeneity. We hypothesize that MM subjugates various ME components, perhaps in a MM subtype-specific manner, and that such MM-induced ME imprints may become an irreversible force, contributing







1. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents.N Engl J Med. 1984 May 24;310(21):1353-6.PMID: 6546971

2.Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.N Engl J Med. 1994 Mar 3;330(9):602-5. No abstract available. PMID: 8302342

3. Tian E, Zhan F, Walker R, Rasmus-

sen E, Ma Y, Barlogie B, Shaughnessy

JD Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003 Dec 25;349(26):2483-94. PMID: 14695408 4. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17.

5.Barlogie B. The role of transplant in multiple myeloma. Clin Adv Hematol Oncol 2005; 3: 604-606. PMID:16167043

6. Zangari M, Esseltine D, Lee CK,

PMID: 12826635

Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Hematol 2005; 131: 71-73. PMID:16399589 7. Shaughnessy JD Jr, Barlogie B. Using genomics to identify high-risk Myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12 (1 Suppl 1):77-80. PMID:16399589

8. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. N Engl J Med 2006; 354:1021-1030. PMID:16525139

